Elebsiran is a subcutaneous investigational siRNA therapy designed to degrade hepatitis B virus RNA, thereby reducing surface antigen production. It has shown potential antiviral activity against both ...
The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results